Doxycycline prevents acute pulmonary embolism-induced mortality and right ventricular deformation in rats

Cardiovascular Drugs and Therapy

Volumn 27, Issue 4, 2013, Pages 259-267

  Cau, Stefany B A ^a   Barato, Renan C ^a   Celes, Mara R ^a,b   Muniz, Jaqueline J ^c   Rossi, Marcos A ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Acute pulmonary embolism; Doxycycline; MMP 9; Right ventricular damage

Indexed keywords

DOXYCYCLINE; GELATINASE A; GELATINASE B; HYDROETHIDINE; MATRIX METALLOPROTEINASE; MICROSPHERE; MYELOPEROXIDASE; REACTIVE OXYGEN METABOLITE; STROMELYSIN;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMEGALY; CONTROLLED STUDY; DEATH; ENZYME ACTIVITY; ENZYME INHIBITION; FOLLOW UP; HEART; HEART DILATATION; HEART INJURY; HEART RIGHT VENTRICLE DEFORMATION; HEART RIGHT VENTRICLE FAILURE; HISTOLOGY; LUNG EMBOLISM; MORPHOMETRICS; MORTALITY; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PHARMACOLOGICAL BLOCKING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SINGLE DRUG DOSE; TISSUE HOMOGENATE; WISTAR RAT; ZYMOGRAPHY;

ANIMALS; DOXYCYCLINE; HEART VENTRICLES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; PULMONARY EMBOLISM; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES;

EID: 84880252976     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-013-6458-9     Document Type: Article

References (32)

1. Wood KE. Major pulmonary embolism: Review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest. 2002;121:877-905.
2. Watts JA, Marchick MR, Kline JA. Right ventricular heart failure from pulmonary embolism: Key distinctions from chronic pulmonary hypertension. J Card Fail. 2010;16:250-9.
3. Lualdi JC, Goldhaber SZ. Right ventricular dysfunction after acute pulmonary embolism: Pathophysiologic factors, detection, and therapeutic implications. Am Heart J. 1995;130:1276-82.
4. Watts JA, Gellar MA, Obraztsova M, Kline JA, Zagorski J. Role of inflammation in right ventricular damage and repair following experimental pulmonary embolism in rats. Int J Exp Pathol. 2008;89:389-99.
5. Watts JA, Zagorski J, Gellar MA, Stevinson BG, Kline JA. Cardiac inflammation contributes to right ventricular dysfunction following experimental pulmonary embolism in rats. J Mol Cell Cardiol. 2006;41:296-307.
6. Zagorski J, Gellar MA, Obraztsova M, Kline JA, Watts JA. Inhibition of cinc-1 decreases right ventricular damage caused by experimental pulmonary embolism in rats. J Immunol. 2007;179:7820-6.
7. Iwadate K, Doi M, Tanno K, et al. Right ventricular damage due to pulmonary embolism: Examination of the number of infiltrating macrophages. Forensic Sci Int. 2003;134:147-53.
8. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res. 2004;61:481-97.
9. Hobeika MJ, Thompson RW, Muhs BE, Brooks PC, Gagne PJ. Matrix metalloproteinases in peripheral vascular disease. J Vasc Surg. 2007;45:849-57.
10. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: Rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol. 2007;47:211-42.
11. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol. 2007;152:189-205.
12. Ali MA, Cho WJ, Hudson B, et al. Titin is a target of matrix metalloproteinase-2: Implications in myocardial ischemia/reperfusion injury. Circulation. 2010;122:2039-47.
13. Palei AC, Zaneti RA, Fortuna GM, Gerlach RF, Tanus-Santos JE. Hemodynamic benefits of matrix metalloproteinase-9 inhibition by doxycycline during experimental acute pulmonary embolism. Angiology. 2005;56:611-7.
14. Neto-Neves EM, Dias-Junior CA, Rizzi E, et al. Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism. Crit Care Med. 2011;39:349-56.
15. Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of action. Pharmacol Res. 2011;63:102-7.
16. Souza-Costa DC, Figueiredo-Lopes L, Alves-Filho JC, et al. Protective effects of atorvastatin in rat models of acute pulmonary embolism: Involvement of matrix metalloproteinase-9. Crit Care Med. 2007;35:239-45.
17. Jacob-Ferreira AL, Palei AC, Cau SB, et al. Evidence for the involvement of matrix metalloproteinases in the cardiovascular effects produced by nicotine. Eur J Pharmacol. 2010;627:216-22.
18. Rizzi E, Castro MM, Prado CM, et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail. 2010;16:599-608.
19. Sousa-Santos O, Neto-Neves EM, Ferraz KC, et al. Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism. Naunyn Schmiedebergs Arch Pharmacol. 2012;385:685-96.
20. Rizzi E, Castro MM, Ceron CS, et al. Tempol inhibits tgf-beta and mmps upregulation and prevents cardiac hypertensive changes. Int J Cardiol 2011
21. Sanchez O, Trinquart L, Colombet I, et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: A systematic review. Eur Heart J. 2008;29:1569-77.
22. Faurschou M, Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect. 2003;5:1317-27.
23. Rouet-Benzineb P, Buhler JM, Dreyfus P, et al. Altered balance between matrix gelatinases (mmp-2 and mmp-9) and their tissue inhibitors in human dilated cardiomyopathy: Potential role of mmp-9 in myosin-heavy chain degradation. Eur J Heart Fail. 1999;1:337-52.
24. Uzuelli JA, Dias-Junior CA, Tanus-Santos JE. Severity dependent increases in circulating cardiac troponin i and mmp-9 concentrations after experimental acute pulmonary thromboembolism. Clin Chim Acta. 2008;388:184-8.
25. Fortuna GM, Figueiredo-Lopes L, Dias-Junior CA, Gerlach RF, Tanus-Santos JE. A role for matrix metalloproteinase-9 in the hemodynamic changes following acute pulmonary embolism. Int J Cardiol. 2007;114:22-7.
26. Souza-Costa DC, Zerbini T, Palei AC, Gerlach RF, Tanus-Santos JE. L-arginine attenuates acute pulmonary embolism-induced increases in lung matrix metalloproteinase-2 and matrix metalloproteinase-9. Chest. 2005;128:3705-10.
27. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999;85:906-11.
28. Fernandez-Patron C, Zouki C, Whittal R, et al. Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1[1-32]. FASEB J. 2001;15:2230-40.
29. Tanus-Santos JE, Gordo WM, Udelsmann A, Cittadino MH, Moreno Jr H. Nonselective endothelin-receptor antagonism attenuates hemodynamic changes after massive pulmonary air embolism in dogs. Chest. 2000;118:175-9.
30. Tanus-Santos JE, Gordo WM, Udelsmann A, Moreno Jr H. The hemodynamic effects of endothelin receptor antagonism during a venous air infusion in dogs. Anesth Analg. 2000;90:102-6.
31. Kraus RL, Pasieczny R, Lariosa-Willingham K, et al. Antioxidant properties of minocycline: Neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem. 2005;94:819-27.
32. Castro MM, Tanus-Santos JE, Gerlach RF. Matrix metalloproteinases: Targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res. 2011;64:567-72. São Paulo